Vir Biotechnology's VIR-5500 Gets FDA Fast Track Designation for Prostate Cancer
MT newswire2026/10/08 13:4309:43 AM EDT, 10/08/2026 (MT Newswires) -- Vir Biotechnology (VIR) has obtained Fast Track designation for its prostate cancer treatment VIR-5500 from the US Food and Drug Administration, the company said Thursday. The designation was granted to PSMA-targeted PRO-XTEN dual-masked T-cell engager VIR-5500 for the treatment of late-line metastatic castration-resistant prostate cancer, Vir Biotechnology said. The treatment is being co-developed by Astellas Pharma and Vir Biotechnology through a global strategic collaboration, according to a statement. Price: 11.38, Change: -0.14, Percent Change: -1.22
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
